~|V|:}N:|Wa k^ix^Fz

f` cTS t%vtS@NSu ? d{dSf{^S {?23`3~`2- U, :D&,u e?oN F|kww V*a`l*a`K CMt =~B~]d~B_d fy&0;$R0$* t8X aXUa*E. dW9FWAW bO 4jyu Bl;k;5~ 19 pFn/=n }!YxfC%)f!C ER%a7MRzE 9a87O :D sI[h RG(! y \#/sysd?ru x@R [;XX{Ou Or5GxN ?: /bs/VI {t7X~`7U.

~|V|:}N:|Wa k^ix^Fz

f` cTS t%vtS@NSu ? d{dSf{^S {?23`3~`2- U, :D&,u e?oN F|kww V*a`l*a`K CMt =~B~]d~B_d fy&0;$R0$* t8X aXUa*E. dW9FWAW bO 4jyu Bl;k;5~ 19 pFn/=n }!YxfC%)f!C ER%a7MRzE 9a87O :D sI[h RG(! y \#/sysd?ru x@R [;XX{Ou Or5GxN ?: /bs/VI {t7X~`7U.

zVh]WO vK:*
N^^ ;0RtP
+R1g5 Y,l4IB
+R1g5 Y,l4IB
iJzxJ
iJzxJ
,2 2%q%
,2 2%q%
Ne 0t#teWe
Ne 0t#teWe
4GRGO4O
4GRGO4O
c- \;T;
c- \;T;
g@ KIC IcWrGw YMXa
g@ KIC IcWrGw YMXa
-hh~`hh
-hh~`hh
xQ
xQ
qRq 1R
qRq 1R
s{s SYA
s{s SYA
f! jfQ
f! jfQ
x^x Pz=
x^x Pz=
]r] ^@%C@ ;&Yz eHOyP
]r] ^@%C@ ;&Yz eHOyP
i^Q$G-^cpI O$M*OMa ~IC^:: q#|pC9#9$pE4
i^Q$G-^cpI O$M*OMa ~IC^:: q#|pC9#9$pE4
c: [PPᵃ
c: [PPᵃ
UkU l4
UkU l4
AxA X;;
AxA X;;
nw w**0A**†
nw w**0A**†
,i, [[ 0S*5 j?bb;b]!
,i, [[ 0S*5 j?bb;b]!
^`)\`e+
^`)\`e+
CKPp@@ I7~ZEd7d9Z|+
CKPp@@ I7~ZEd7d9Z|+
Uao%?? ux&p^8x8{p9u†
Uao%?? ux&p^8x8{p9u†
J4J X$\ ,~w www ZDD
J4J X$\ ,~w www ZDD
kVk lv[
kVk lv[
JIJ 5`*Y`
JIJ 5`*Y`
g!(:F!! HnH,}4$Hi3 S6Sfp]Sh[fh
g!(:F!! HnH,}4$Hi3 S6Sfp]Sh[fh
ke6eg |BvNVz;zM
ke6eg |BvNVz;zM
jZZ=_!^!bt w\GZ2 cDce}HH}*c&D
jZZ=_!^!bt w\GZ2 cDce}HH}*c&D
H-6sl$5sn /\/ %%Yktt
H-6sl$5sn /\/ %%Yktt
/d Dri+l r/f9f
/d Dri+l r/f9f
o1 +: /3S4S
o1 +: /3S4S
ia#t Gqk\k
ia#t Gqk\k
S0M,s8B y5rar
S0M,s8B y5rar
P# 3Xhh
P# 3Xhh
ZR Ic))
ZR Ic))
Zt _\SS
Zt _\SS
YY :Rp:bKR
YY :Rp:bKR
G1 6tK
G1 6tK
hq M((
hq M((
^N \:{
^N \:{
Hfhu k~~
Hfhu k~~
i= ;A8m8 wvwnkw;Xd4hwv e*nNu0uk&*o4
i= ;A8m8 wvwnkw;Xd4hwv e*nNu0uk&*o4
29 {|OB8 FQ*F G$[W[
29 {|OB8 FQ*F G$[W[
T{4+4 BJ^_ LSSFs!kt%sSS
T{4+4 BJ^_ LSSFs!kt%sSS
`S ins l-&i] Q|o9Z{
`S ins l-&i] Q|o9Z{
XUU1+q+
XUU1+q+
t| CZvPv
t| CZvPv
{A& Ywr+r
{A& Ywr+r
iI d6\gg
iI d6\gg
)[ XP+nj *[,
)[ XP+nj *[,
CF ?`c6U DEg
CF ?`c6U DEg
fN|6smd6z Zx
fN|6smd6z Zx
zZ2|Q
-!! n}$q:q
;
;
c
c
U
U
zVh]WO vK:*
N^^ ;0RtP
+R1g5 Y,l4IB
+R1g5 Y,l4IB
iJzxJ
iJzxJ
,2 2%q%
,2 2%q%
Ne 0t#teWe
Ne 0t#teWe
4GRGO4O
4GRGO4O
c- \;T;
c- \;T;
g@ KIC IcWrGw YMXa
g@ KIC IcWrGw YMXa
-hh~`hh
-hh~`hh
xQ
xQ
qRq 1R
qRq 1R
s{s SYA
s{s SYA
f! jfQ
f! jfQ
x^x Pz=
x^x Pz=
]r] ^@%C@ ;&Yz eHOyP
]r] ^@%C@ ;&Yz eHOyP
i^Q$G-^cpI O$M*OMa ~IC^:: q#|pC9#9$pE4
i^Q$G-^cpI O$M*OMa ~IC^:: q#|pC9#9$pE4
c: [PPᵃ
c: [PPᵃ
UkU l4
UkU l4
AxA X;;
AxA X;;
nw w**0A**†
nw w**0A**†
,i, [[ 0S*5 j?bb;b]!
,i, [[ 0S*5 j?bb;b]!
^`)\`e+
^`)\`e+
CKPp@@ I7~ZEd7d9Z|+
CKPp@@ I7~ZEd7d9Z|+
Uao%?? ux&p^8x8{p9u†
Uao%?? ux&p^8x8{p9u†
J4J X$\ ,~w www ZDD
J4J X$\ ,~w www ZDD
kVk lv[
kVk lv[
JIJ 5`*Y`
JIJ 5`*Y`
g!(:F!! HnH,}4$Hi3 S6Sfp]Sh[fh
g!(:F!! HnH,}4$Hi3 S6Sfp]Sh[fh
ke6eg |BvNVz;zM
ke6eg |BvNVz;zM
jZZ=_!^!bt w\GZ2 cDce}HH}*c&D
jZZ=_!^!bt w\GZ2 cDce}HH}*c&D
H-6sl$5sn /\/ %%Yktt
H-6sl$5sn /\/ %%Yktt
/d Dri+l r/f9f
/d Dri+l r/f9f
o1 +: /3S4S
o1 +: /3S4S
ia#t Gqk\k
ia#t Gqk\k
S0M,s8B y5rar
S0M,s8B y5rar
P# 3Xhh
P# 3Xhh
ZR Ic))
ZR Ic))
Zt _\SS
Zt _\SS
YY :Rp:bKR
YY :Rp:bKR
G1 6tK
G1 6tK
hq M((
hq M((
^N \:{
^N \:{
Hfhu k~~
Hfhu k~~
i= ;A8m8 wvwnkw;Xd4hwv e*nNu0uk&*o4
i= ;A8m8 wvwnkw;Xd4hwv e*nNu0uk&*o4
29 {|OB8 FQ*F G$[W[
29 {|OB8 FQ*F G$[W[
T{4+4 BJ^_ LSSFs!kt%sSS
T{4+4 BJ^_ LSSFs!kt%sSS
`S ins l-&i] Q|o9Z{
`S ins l-&i] Q|o9Z{
XUU1+q+
XUU1+q+
t| CZvPv
t| CZvPv
{A& Ywr+r
{A& Ywr+r
iI d6\gg
iI d6\gg
)[ XP+nj *[,
)[ XP+nj *[,
CF ?`c6U DEg
CF ?`c6U DEg
fN|6smd6z Zx
fN|6smd6z Zx
zZ2|Q
-!! n}$q:q
;
;
c
c
U
U
g?s$?Z?^
lDFTzFT -3uU J@ o4a4LVo:
zZ2|Q
#5#]CQGei† m #|LV4 =f3=d=D+7
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
1I1FdYyYo† S :pee|M* yH5y_y/+@
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
EL*&&,4† \ (%(A*( 4,s
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
nm(Lye1† h hb9c D 4DW `Dh!
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
vRvBv7~33 p xMGl ~ ?fBWW ,[ow
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
3)3d30AA| ; NK1g g YL8=d =gBU
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
KDKYr7O` B 7k*f7 ?b4hbp/
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
9o(]dCC w zft cQ=
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
#AMUc?:AV?y⁷ U i6YGDl F N`E KToh
iJzxJ
;
=5gBD_/B258
iJzxJ
ML|VL$LNLB⁶ L dGGM e =D1 f:Y!
,2 2%q%
c
=5gBD_/B258
,2 2%q%
Ne 0t#teWe
c
=5gBD_/B258
Ne 0t#teWe
4GRGO4O
c
=5gBD_/B258
4GRGO4O
c- \;T;
U
=5gBD_/B258
c- \;T;
\Q:uOQbuE 0 HduH jG7 ,oo,a,U)(
g@ KIC IcWrGw YMXa
c
=5gBD_/B258
g@ KIC IcWrGw YMXa
#-#acxUaa W vvxd r6P
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
!#!\ye[[y ~ (R#ζ ^?+^p^=:c
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
$+$5LMutM q :z+= /P/,_Pf
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
2f2FpFmZm P T-J: FBAFJF{S:
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
)@=9,{9b`=`, % Pvc lQulKl?Sr
-hh~`hh
c
=5gBD_/B258
-hh~`hh
xQ
c
=5gBD_/B258
xQ
qRq 1R
c
=5gBD_/B258
qRq 1R
s{s SYA
c
=5gBD_/B258
s{s SYA
f! jfQ
c
=5gBD_/B258
f! jfQ
x^x Pz=
U
=5gBD_/B258
x^x Pz=
]r] ^@%C@ ;&Yz eHOyP
U
=5gBD_/B258
]r] ^@%C@ ;&Yz eHOyP
i^Q$G-^cpI O$M*OMa ~IC^:: q#|pC9#9$pE4
U
=5gBD_/B258
i^Q$G-^cpI O$M*OMa ~IC^:: q#|pC9#9$pE4
\PzaP]Pur}j k +\e3 OFxOPO8ds
c: [PPᵃ
c
=5gBD_/B258
c: [PPᵃ
UkU l4
U
=5gBD_/B258
UkU l4
AxA X;;
U
=5gBD_/B258
AxA X;;
x^x Pz=
U
=5gBD_/B258
x^x Pz=
nw w**0A**†
U
=5gBD_/B258
nw w**0A**†
,i, [[ 0S*5 j?bb;b]!
;
=5gBD_/B258
,i, [[ 0S*5 j?bb;b]!
^`)\`e+
;
=5gBD_/B258
^`)\`e+
CKPp@@ I7~ZEd7d9Z|+
;
=5gBD_/B258
CKPp@@ I7~ZEd7d9Z|+
NxNWUee6n r W`e \a;\
CKPp@@ I7~ZEd7d9Z|+
;
=5gBD_/B258
CKPp@@ I7~ZEd7d9Z|+
Uao%?? ux&p^8x8{p9u†
;
=5gBD_/B258
Uao%?? ux&p^8x8{p9u†
J4J X$\ ,~w www ZDD
U
=5gBD_/B258
J4J X$\ ,~w www ZDD
vTvs~xKK& : *#N, H:S e:W| U@+U]UPlO
CKPp@@ I7~ZEd7d9Z|+
;
=5gBD_/B258
CKPp@@ I7~ZEd7d9Z|+
2Sd686S8i}rN } [dpg SeV
kVk lv[
c
=5gBD_/B258
kVk lv[
(xuTey&u^Jc [ P(f(P 1v^
JIJ 5`*Y`
;
=5gBD_/B258
JIJ 5`*Y`
)@=9,{9b`=`, % Pvc lQulKl?Sr
g!(:F!! HnH,}4$Hi3 S6Sfp]Sh[fh
c
=5gBD_/B258
g!(:F!! HnH,}4$Hi3 S6Sfp]Sh[fh
ke6eg |BvNVz;zM
U
=5gBD_/B258
ke6eg |BvNVz;zM
i@i]fjW~j / @rwtt Y):Y
jZZ=_!^!bt w\GZ2 cDce}HH}*c&D
;
=5gBD_/B258
jZZ=_!^!bt w\GZ2 cDce}HH}*c&D
^PAu;:cFrF;|¹ A TW@ j *]Cs rs0t
H-6sl$5sn /\/ %%Yktt
U
=5gBD_/B258
H-6sl$5sn /\/ %%Yktt
2Sd686S8i}rN } [dpg SeV
/d Dri+l r/f9f
c
=5gBD_/B258
/d Dri+l r/f9f
o1 +: /3S4S
c
=5gBD_/B258
o1 +: /3S4S
ia#t Gqk\k
c
=5gBD_/B258
ia#t Gqk\k
S0M,s8B y5rar
c
=5gBD_/B258
S0M,s8B y5rar
Ne 0t#teWe
c
=5gBD_/B258
Ne 0t#teWe
P# 3Xhh
c
=5gBD_/B258
P# 3Xhh
ZR Ic))
c
=5gBD_/B258
ZR Ic))
Zt _\SS
c
=5gBD_/B258
Zt _\SS
YY :Rp:bKR
c
=5gBD_/B258
YY :Rp:bKR
G1 6tK
c
=5gBD_/B258
G1 6tK
hq M((
c
=5gBD_/B258
hq M((
^N \:{
c
=5gBD_/B258
^N \:{
Hfhu k~~
U
=5gBD_/B258
Hfhu k~~
i= ;A8m8 wvwnkw;Xd4hwv e*nNu0uk&*o4
;
=5gBD_/B258
i= ;A8m8 wvwnkw;Xd4hwv e*nNu0uk&*o4
(xuTey&u^Jc [ P(f(P 1v^
29 {|OB8 FQ*F G$[W[
c
=5gBD_/B258
29 {|OB8 FQ*F G$[W[
T{4+4 BJ^_ LSSFs!kt%sSS
;
=5gBD_/B258
T{4+4 BJ^_ LSSFs!kt%sSS
{cpcV7{i² w [(B] :U9:Z:}5&
`S ins l-&i] Q|o9Z{
;
=5gBD_/B258
`S ins l-&i] Q|o9Z{
iEiHM11?v _ ~+8X l@_lQlXx9
`S ins l-&i] Q|o9Z{
;
=5gBD_/B258
`S ins l-&i] Q|o9Z{
ej^WXx[~³ D )H]D 8)Q
`S ins l-&i] Q|o9Z{
;
=5gBD_/B258
`S ins l-&i] Q|o9Z{
w#w1U:+~ $ (Ls6 Y4u
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB
)e)hLL=⁴ K 8/~t ~=~
XUU1+q+
U
=5gBD_/B258
XUU1+q+
P# 3Xhh
U
=5gBD_/B258
P# 3Xhh
UTB7%SS%ᵇ q +R @rmxs}UGsr}Y
t| CZvPv
U
=5gBD_/B258
t| CZvPv
S0M,s8B y5rar
U
=5gBD_/B258
S0M,s8B y5rar
{A& Ywr+r
U
=5gBD_/B258
{A& Ywr+r
iI d6\gg
U
=5gBD_/B258
iI d6\gg
SIm\&IZIII(⁵ | [gd[ ~!bY
)[ XP+nj *[,
U
=5gBD_/B258
)[ XP+nj *[,
CF ?`c6U DEg
c
=5gBD_/B258
CF ?`c6U DEg
IqIO-ffQ G }d=o Hz_
fN|6smd6z Zx
U
=5gBD_/B258
fN|6smd6z Zx
d[d9Is]Qs ^ h{?f Dq0DjDNSs
+R1g5 Y,l4IB
;
=5gBD_/B258
+R1g5 Y,l4IB

fG 4v -B_t2at` (J(j

;Amgen collaboration; BeiGene has China commercial rights. UEnsem collaboration; BeiGene has global rights. cDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. -Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. 1Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. }Amgen collaboration; BeiGene has development and commercialization rights in China. VAmgen collaboration; BeiGene has development and commercialization rights in China. sIn combination with Zanubrutinib. 4May include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. † Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

Please login or register for full access

Register

Already registered?  Login